For the quarter ending 2025-09-30, CTSO has $45,750K in assets. $36,730K in debts. $7,536K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 7,536 | 10,204 | ||
| Accounts receivable, net of allowances of 134 and 158 as of september 30, 2025 and december 31, 2024, respectively | 7,427 | 7,743 | ||
| Inventories | 4,002 | 3,710 | ||
| Prepaid expenses and other current assets | 2,348 | 1,330 | ||
| Total current assets | 21,313 | 22,987 | ||
| Property and equipment, gross | 13,482 | - | ||
| Less accumulated depreciation and amortization | 5,289 | - | ||
| Property and equipment - net | 8,193 | 8,466 | ||
| Restricted cash | 1,522 | 1,522 | ||
| Right-of-use asset | 11,075 | 11,223 | ||
| Other assets | 3,647 | 3,792 | ||
| Total assets | 45,750 | 47,990 | ||
| Accounts payable | 3,035 | 3,394 | ||
| Accrued expenses and other current liabilities | 6,559 | 5,953 | ||
| Lease liability - current portion | 518 | 495 | ||
| Total current liabilities | 10,112 | 9,842 | ||
| Lease liability, net of current portion | 12,051 | 12,185 | ||
| Long-term debt | 14,567 | 14,377 | ||
| Total liabilities | 36,730 | 36,404 | ||
| Common stock, par value 0.001, 100,000,000 shares authorized as of september 30, 2025 and december 31, 2024 62,794,305 and 54,830,146 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 63 | 63 | ||
| Additional paid-in capital | 319,511 | 319,023 | ||
| Accumulated other comprehensive income (loss) | -3,844 | -3,960 | ||
| Accumulated deficit | -306,710 | -303,540 | ||
| Total stockholders' equity | 9,020 | 11,586 | ||
| Total liabilities and stockholders' equity | 45,750 | 47,990 | ||
Cytosorbents Corp (CTSO)
Cytosorbents Corp (CTSO)